Cell Medica treats first patient in CMV IMAPACT trial

London, UK-based Cell Medica has treated the initial patients in the first-ever study comparing the efficacy of adoptive cell therapy against conventional antiviral drug treatment for cytomegalovirus infections.

The late-stage randomized confirmatory trial is aimed at demonstrating the clinical effectiveness of immunoprophylactic adoptive cellular therapy (IMPACT) for the treatment of CMV in immunosuppressed patients.

Funded by the Wellcome Trust through a Translation Award, Cell Medica says the trial is an essential step to establish adoptive cell therapy as routine clinical practice for the treatment of patients at high-risk of CMV infection following a bone marrow transplant.